Zeno Equity Partners LLP Has $20.18 Million Position in Medpace Holdings, Inc. (NASDAQ:MEDP)

Zeno Equity Partners LLP grew its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 24.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 60,740 shares of the company's stock after purchasing an additional 12,121 shares during the period. Medpace makes up 6.1% of Zeno Equity Partners LLP's portfolio, making the stock its 9th biggest holding. Zeno Equity Partners LLP owned 0.20% of Medpace worth $20,180,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. GSA Capital Partners LLP purchased a new stake in Medpace during the third quarter valued at about $276,000. KBC Group NV lifted its stake in Medpace by 5.5% during the third quarter. KBC Group NV now owns 1,213 shares of the company's stock valued at $405,000 after buying an additional 63 shares in the last quarter. Natixis Advisors LLC purchased a new stake in Medpace during the third quarter valued at about $3,754,000. Mutual of America Capital Management LLC lifted its position in shares of Medpace by 1.9% in the third quarter. Mutual of America Capital Management LLC now owns 13,738 shares of the company's stock worth $4,586,000 after purchasing an additional 255 shares in the last quarter. Finally, Thrivent Financial for Lutherans lifted its position in shares of Medpace by 61.3% in the third quarter. Thrivent Financial for Lutherans now owns 14,430 shares of the company's stock worth $4,817,000 after purchasing an additional 5,484 shares in the last quarter. Institutional investors own 77.98% of the company's stock.

Analysts Set New Price Targets

Separately, Robert W. Baird increased their price target on shares of Medpace from $354.00 to $362.00 and gave the stock a "neutral" rating in a research report on Monday, January 27th. Seven research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, Medpace presently has a consensus rating of "Hold" and a consensus price target of $381.44.

Remove Ads

Medpace Trading Up 1.4 %

MEDP stock traded up $4.60 during midday trading on Friday, hitting $324.23. The stock had a trading volume of 434,202 shares, compared to its average volume of 289,354. The firm has a market capitalization of $9.88 billion, a price-to-earnings ratio of 25.67, a P/E/G ratio of 3.81 and a beta of 1.47. Medpace Holdings, Inc. has a 52 week low of $302.01 and a 52 week high of $459.77. The stock has a 50-day simple moving average of $337.72 and a 200 day simple moving average of $339.77.

Medpace (NASDAQ:MEDP - Get Free Report) last issued its earnings results on Monday, February 10th. The company reported $3.67 EPS for the quarter, topping the consensus estimate of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. On average, equities analysts forecast that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.